Mankind Pharma’s Rajeev Juneja plots path to No.1 spot, says BSV deal validates bold bets as debt falls
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓Mankind Pharma aims to become India’s top drugmaker as its debt fell to Rs 2,639 crore.
- ✓Vice Chairman Rajeev Juneja said the Bharat Serums and Vaccines deal validates bold bets.
- ✓The company reported revenue of Rs 14,278 crore in FY26 and now plans to focus on innovation and chronic therapies.
Story at a Glance
- Category
- Indian Markets
- Reported By
- Moneycontrol
- Reading Speed
- 7 Minute(s)
- Market Focus
- India Economy
Market Mastery
Webinar by Vishal Malkan
Find the weak links
in your portfolio by Vishal Malkan
Mankind Pharma's ambition to become India's No. 1 domestic drugmaker is no longer a distant dream, Vice Chairman and Managing Director Rajeev Juneja said in an exclusive interview with Moneycontrol, adding that the company's improving balance sheet, rising cash generation and successful integration of the Rs 14,000-crore Bharat Serums and Vaccines (BSV) acquisition have put it on a stronger footing to chase the top spot.
After reducing net debt to Rs 2,639 crore and guiding for acquisition debt repayment by FY28, Mankind is now preparing to deploy capital towards innovation, chronic therapies and selective acquisitions, while building a more decentralised organisation led by specialised business heads.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
Moneycontrol
Read the full, original unfiltered story directly on the publisher's portal.
This brief is for information only and is not investment advice. ArthNow is not a SEBI-registered investment adviser and does not publish buy or sell recommendations. Original reporting is credited to the publisher named above. Read our editorial policy or report an error.